Daré Bioscience Statistics
Total Valuation
Daré Bioscience has a market cap or net worth of $31.59 million. The enterprise value is $14.69 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Daré Bioscience has 14.56 million shares outstanding. The number of shares has increased by 46.86% in one year.
| Current Share Class | 14.56M |
| Shares Outstanding | 14.56M |
| Shares Change (YoY) | +46.86% |
| Shares Change (QoQ) | +1.66% |
| Owned by Insiders (%) | 0.95% |
| Owned by Institutions (%) | 8.63% |
| Float | 13.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.30 |
| Forward PS | 1.63 |
| PB Ratio | 43.06 |
| P/TBV Ratio | 43.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 2.20.
| Current Ratio | 1.03 |
| Quick Ratio | 0.91 |
| Debt / Equity | 2.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -32.21% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -178.41% |
| Weighted Average Cost of Capital (WACC) | 9.75% |
| Revenue Per Employee | $48,218 |
| Profits Per Employee | -$500,869 |
| Employee Count | 24 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.91% in the last 52 weeks. The beta is 1.09, so Daré Bioscience's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | -24.91% |
| 50-Day Moving Average | 2.03 |
| 200-Day Moving Average | 1.99 |
| Relative Strength Index (RSI) | 44.88 |
| Average Volume (20 Days) | 942,693 |
Short Selling Information
The latest short interest is 358,082, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 358,082 |
| Short Previous Month | 170,167 |
| Short % of Shares Out | 2.46% |
| Short % of Float | 2.69% |
| Short Ratio (days to cover) | 0.43 |
Income Statement
In the last 12 months, Daré Bioscience had revenue of $1.16 million and -$12.02 million in losses. Loss per share was -$0.96.
| Revenue | 1.16M |
| Gross Profit | 619,097 |
| Operating Income | -11.97M |
| Pretax Income | -12.02M |
| Net Income | -12.02M |
| EBITDA | -9.96M |
| EBIT | -11.97M |
| Loss Per Share | -$0.96 |
Full Income StatementBalance Sheet
The company has $18.52 million in cash and $1.61 million in debt, with a net cash position of $16.91 million or $1.16 per share.
| Cash & Cash Equivalents | 18.52M |
| Total Debt | 1.61M |
| Net Cash | 16.91M |
| Net Cash Per Share | $1.16 |
| Equity (Book Value) | 734,451 |
| Book Value Per Share | 0.05 |
| Working Capital | 540,124 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.94 million and capital expenditures -$227,947, giving a free cash flow of -$10.16 million.
| Operating Cash Flow | -9.94M |
| Capital Expenditures | -227,947 |
| Depreciation & Amortization | 2.01M |
| Net Borrowing | -2.22M |
| Free Cash Flow | -10.16M |
| FCF Per Share | -$0.70 |
Full Cash Flow StatementMargins
| Gross Margin | 53.50% |
| Operating Margin | -1,034.38% |
| Pretax Margin | -1,038.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Daré Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.86% |
| Shareholder Yield | -46.86% |
| Earnings Yield | -38.05% |
| FCF Yield | -32.17% |
Analyst Forecast
The average price target for Daré Bioscience is $10.00, which is 360.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 360.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 128.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jul 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
